Ratings by Guggenheim (Paul Jeng)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 10/21/2026 | Kazia Therapeutics | KZIA | New Coverage | Buy (N/A) |
0.00 (8.18) |
0% | Details | |
| 9/15/2026 | Nanobiotix S.A | NBTX | New Coverage | Buy (N/A) |
35.73 (25.83) |
-27.71% | Details | |
| 9/9/2026 | Ideaya Biosciences | IDYA | Maintain | Buy (N/A) |
|
Details | ||
| 7/14/2026 | Adagene Inc | ADAG | Maintain | Buy (Buy) |
|
Details | ||
| 4/28/2026 | Corbus Pharmaceuticals | CRBP | New Coverage | Buy (N/A) |
10.08 (4.29) |
-57.44% | Details | |
| 4/14/2026 | Ideaya Biosciences | IDYA | Maintain | Buy (N/A) |
|
Details | ||
| 4/6/2026 | Adagene Inc | ADAG | Maintain | Buy (N/A) |
|
Details | ||
| 11/24/2025 | Adagene Inc | ADAG | New Coverage | Buy (N/A) |
1.80 (2.41) |
33.89% | Details | |
| 11/18/2025 | Immatics | IMTX | Maintain | Buy (N/A) |
|
Details | ||
| 9/18/2025 | Immunocore Holdings | IMCR | New Coverage | Neutral (N/A) |
33.81 (32.09) |
-5.09% | Details | |
| 9/18/2025 | Immatics | IMTX | New Coverage | Buy (N/A) |
6.00 (7.69) |
28.17% | Details | |
| 9/18/2025 | Context Therapeutics | CNTX | New Coverage | Buy (N/A) |
0.85 (0.23) |
-72.94% | Details | |
| 9/17/2025 | Ideaya Biosciences | IDYA | New Coverage | Buy (N/A) |
24.72 (35.47) |
43.49% | Details | |
| 7/29/2020 | Artara Therapeutics Inc. | TARA | New Coverage | Buy (N/A) |
27.45 (2.50) |
-90.89% | Details |
